Blood Cancer Talks Podcast
Blood Cancer Talks Podcast
  • 34
  • 16 729
ASH 2024 Myeloma Update with Dr. Rakesh Popat
In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:
1. AQUILA Trial in High-Risk SMM
Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
Insights into modes of progression and the adequacy of active surveillance.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper201057.html
Read the simultaneous publication at NEJM: www.nejm.org/
2. Anito-Cel: New BCMA CAR T Therapy
Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper198499.html
3. CARTITUDE-4 Update
Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper201533.html
4. ANDROMEDA OS Data in AL Amyloidosis
Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
Insights into cardiac responses and crossover impact.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper203858.html
5. OPTIMUM Trial in Ultra-High-Risk NDMM
Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents.
Subgroup outcomes highlighting both challenges and exceptional results.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper201057.html
6. GMMG-HD7 Trial PFS Update
Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT.
Discussion on the role of CD38 in maintenance therapy.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper198499.html
Read the simultaneous publication at JCO: ascopubs.org/journal/jco
7. Exciting New Drugs
Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
Expert insights into their efficacy and potential to reshape myeloma care.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper201533.html
Переглядів: 62

Відео

ASH 2024 Lymphoma and CLL Highlights
Переглядів 36221 день тому
In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: ash.confex.com/ash/2024/webprogram/Paper200735.html b) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP ...
Belantamab Makes a Comeback with Dr. Hang Quach
Переглядів 1032 місяці тому
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. pubmed.ncbi.nlm.nih.gov/38828951/...
Management of Older Adults with Hodgkin Lymphoma with Dr. Andrew Evens
Переглядів 872 місяці тому
In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: pubmed.ncbi.nlm.nih.gov/34162178/ 3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: p...
Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma
Переглядів 1814 місяці тому
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): pubmed.ncbi.nlm.nih.gov/34655533...
Updates in Low Risk MDS with Dr. Max Stahl
Переглядів 1815 місяців тому
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed 3. COMMANDS trial : Lu...
Management of Polycythemia Vera with Dr. Aaron Gerds
Переглядів 1,8 тис.5 місяців тому
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3. MAJIC PV study ascopubs.org/doi/10.1200/JCO.22.01935?url_ve...
ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni
Переглядів 5616 місяців тому
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-P...
Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi
Переглядів 6017 місяців тому
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. Here are the key studies we discussed: 1. GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. www.nature.com/articles/s41375-018-0107-z 2. MIPSS70 Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primar...
Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin
Переглядів 6858 місяців тому
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): pubmed.ncbi...
Essential Thrombocythemia with Dr. Raajit Rampal
Переглядів 2,2 тис.8 місяців тому
In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International 2. The MIPSS-ET provides points for: · ...
Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi
Переглядів 1409 місяців тому
In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.
Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi
Переглядів 13510 місяців тому
In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.
Management of Newly Diagnosed AL Amyloidosis
Переглядів 28010 місяців тому
In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/ 4. Renal staging: pubmed....
ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel
Переглядів 14311 місяців тому
In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelo...
GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan
Переглядів 29611 місяців тому
GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan
ASH 2023 Myeloma Recap with Dr. Ben Derman
Переглядів 1,8 тис.Рік тому
ASH 2023 Myeloma Recap with Dr. Ben Derman
ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Переглядів 437Рік тому
ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson
Переглядів 330Рік тому
Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson
Management of FLT3 positive AML with Dr. Alexander Perl
Переглядів 745Рік тому
Management of FLT3 positive AML with Dr. Alexander Perl
The art of caring for patients at the end of life
Переглядів 74Рік тому
The art of caring for patients at the end of life
t(11;14) Multiple Myeloma and Role of Venetoclax
Переглядів 397Рік тому
t(11;14) Multiple Myeloma and Role of Venetoclax
Management of CNS Lymphoma
Переглядів 526Рік тому
Management of CNS Lymphoma
Management of High-Risk Myeloma
Переглядів 777Рік тому
Management of High-Risk Myeloma
Management of Peripheral T-cell Lymphoma
Переглядів 726Рік тому
Management of Peripheral T-cell Lymphoma
CCUS Uma Borate
Переглядів 105Рік тому
CCUS Uma Borate
Episode 28 Management of newly diagnosed PNH
Переглядів 187Рік тому
Episode 28 Management of newly diagnosed PNH
Managing Acute Toxicities of CAR T-cell Therapy
Переглядів 137Рік тому
Managing Acute Toxicities of CAR T-cell Therapy
ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Переглядів 1,4 тис.Рік тому
ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Bispecific Antibodies in Myeloma
Переглядів 121Рік тому
Bispecific Antibodies in Myeloma

КОМЕНТАРІ

  • @marcpernia8487
    @marcpernia8487 18 днів тому

    Great talk guys!

  • @kcalise3948
    @kcalise3948 Місяць тому

    Are there any studies following asymptomatic PV patients taking toxic Hydroxurea longer than 15 years? Or is it a “wait and see” regarding leukemia risk?

  • @RyanManioni
    @RyanManioni 2 місяці тому

    Thanks so much guys. You give us all hope!

  • @D_XDC
    @D_XDC 2 місяці тому

    Excellent information gents and very well executed

  • @ericlau6435
    @ericlau6435 5 місяців тому

    i really appreciate having this online and the links to the studies. you guys are amazing.

  • @spectator-o8h
    @spectator-o8h 6 місяців тому

    I think another concern is long term or permanent bone marrow suppression. I’ve spoken to someone who did AVO and is still struggling with low red count. I wonder if there should be more scrutiny on patient fitness or risk of CHIP.

  • @clemqueens1943
    @clemqueens1943 6 місяців тому

    Dr Tefferi!!! This podcast should be required for all in the Hematology realm. Dr Tefferi, I want to thank you for your excellent work specifically as it pertains to Myelofibrosis. I do have a wonderful MPN Specialist who saw that my symptoms were warranting an updated BMB which showed MF 2-3. I’m a 62 female who’s been battling an MPN for over 30 years and begging to get a Stem Cell Transplant because my PV caused difficult life altering symptoms. So once the results were back, my wonderful doctor said the soonest we could do it is 3 months and I said “I’M IN!” I may be the only person on the planet who’s excited to get a transplant. Obviously there’s risk but I’d much rather have a chance of being cured than a crappy 1-3 years. Thank you for making this available. I appreciate you all.

  • @faridlalani1259
    @faridlalani1259 6 місяців тому

    😍

  • @johnmalecki3893
    @johnmalecki3893 7 місяців тому

    I hope I have Doctors like her here in Canada. Awesome discussion. Thank you. I am going into Princess Margaret Hospital in Toronto this August for MUD allogeneic transplant for PMF. 70 years old, healthy and fit and currently responding well to Momelotinib at 200 mg daily.

  • @elenascopelliti1211
    @elenascopelliti1211 7 місяців тому

    I was enrolled in manifest-2 protocol in Rome. My life became miserable because I was always ill. I stopped after the virus herpes zoster was riactivated and I suffered a sever facial paralysis. After a year I already have a parcial paralysis and balance problems beacause the VII and VIII cranial nerves was severy injured. I accepted to be enrolled because the doctor told me that otherwise I was going to die for leukemia. That was not true! I didn't have the intermediate-1 grade of mielophibrosis! I only had pre-mielophibrosis! Now I am well cured for pre-mielophibrosis in another roman hospital, only with oncocarbide and booldlettings when necessary, exactly as before I was enrolled in Manifest-2 protocol. I have never have anemia, sweeting or other sintomi, except a bit of fatigue. I've spent 10 thousand euros for the cures. Now I've filed a lawsuit against the hospital. But the law in Italy is really slow and I'll wait 10 years to have justice. The bad news is that I am hughly and parcial disabled, the good news is that I'm not going to die soon as I was told by the doctor who enrolled me in manifest-2!

  • @dininidi5090
    @dininidi5090 7 місяців тому

    It was very nice thanks guys very good questions asked

  • @heysza9905
    @heysza9905 7 місяців тому

    Great interview!

  • @FOTOMOTOGP
    @FOTOMOTOGP 8 місяців тому

    Post bone marrow transplant in August 2022 I started Lenalidomide on its own as maintenance therapy.

  • @FOTOMOTOGP
    @FOTOMOTOGP 8 місяців тому

    Started DVTD. Within weeks suffered peripheral neuropathy. Velcade and Thalidomide stopped. Daratumumab and Dexamethasone took my Paraprotein from 79% to 0%. Daratumumab is a wonder drug.

  • @qunbinxiong4058
    @qunbinxiong4058 10 місяців тому

    Thank you for this presentation!!!

  • @CarolynDenison
    @CarolynDenison 11 місяців тому

    I guess if I already have Secondary CNS Lymphoma I'm pretty much

    • @CarolynDenison
      @CarolynDenison 11 місяців тому

      Think ill look into that today. I'm so sad. Giving up.

  • @stephengillman5087
    @stephengillman5087 Рік тому

    An excellent and informative podcast, your expertise , enthusiasm and humanity gives everyone hope in the future, thank you all .A grateful MCL patient (diagnosed 2009)

  • @linanthony7892
    @linanthony7892 Рік тому

    will be great to have people discuss Manifest-2 and Transform-1

  • @eryilkce
    @eryilkce Рік тому

    Dear Dr Raza and the Podcast Team, many thanks for sharing this emotional talk! <3 C.

  • @hunchhead54
    @hunchhead54 Рік тому

    Thank God for nerds.

  • @AlayMansurov
    @AlayMansurov Рік тому

    Thank you for great podcast and video! I really wanted to find this type of content! Very useful!